Elevation Oncology Announces $65M Series B Financing and Promotion of Founder Shawn M. Leland to Chief Executive Officer
Read More
Elevation Oncology Announces $65M Series B Financing and Promotion of Founder Shawn M. Leland to Chief Executive Officer
NRG1 fusions, a (PDX) model challenge
With the advent of the ‘precision oncology’ movement, the success of biomarker-driven targeted therapies has fundamentally changed our approach to drug development and treatment selection.
Read More 
EORTC-NCI-AACR 2020
The anti-HER3 monoclonal antibody seribantumab effectively inhibits growth of patient-derived and isogenic cell line and xenograft models with NRG1 rearrangements
Read More 
Elevation Oncology Announces the Presentation of Preclinical Data on the Specific Inhibition of HER3 to Block NRG1 Fusion Signaling
Presentation of data at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Read More 
IASLC North America Conference on Lung Cancer 2020
Trial in Progress: the CRESTONE study with Dr. David Spiegel
Read More 
Elevation Oncology and US Oncology Research Announce Collaboration to Expand Genomic Testing of Solid Tumors and Local Site Activation in Support of the Phase 2 CRESTONE Study
Read More 
AACR Special Conference on Pancreatic Cancer 2020
Trial in Progress: the CRESTONE study with Dr. Johanna Bendell
Read More 
Elevation Oncology Emerges from Stealth with $32.5M Series A to Develop Precision Medicines for Tumors Harboring Rare Genetic Driver Alterations
$32.5M Series A Financing Led by Aisling Capital, Vertex Ventures HC, Qiming Venture Partners USA, Driehaus Capital Management, and BVF Partners
Read More